TACE Combined With "Target Immune" Therapy for First-line Treatment in the Treatment of Intrahepatic Cholangiocarcinoma

NCT05247996 · clinicaltrials.gov ↗

NA

Phase

UNKNOWN

Status

98

Enrollment

OTHER

Sponsor class

Conditions

Intrahepatic Cholangiocarcinoma

Interventions

PROCEDURE: Transcatheter arterial chemoembolization
DRUG: Multi-target Drug Therapy
DRUG: Immunocheckpoint Inhibitor Therapy
PROCEDURE: Systemic Intravenous Chemotherapy

Sponsor

The Central Hospital of Lishui City